US Bancorp DE Makes New Investment in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

US Bancorp DE bought a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 33,792 shares of the biotechnology company’s stock, valued at approximately $40,000.

Several other large investors have also added to or reduced their stakes in CTMX. Congress Park Capital LLC boosted its position in shares of CytomX Therapeutics by 393.3% during the 2nd quarter. Congress Park Capital LLC now owns 1,153,220 shares of the biotechnology company’s stock valued at $1,407,000 after acquiring an additional 919,420 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of CytomX Therapeutics by 206.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company’s stock valued at $1,511,000 after acquiring an additional 833,825 shares during the last quarter. Sei Investments Co. bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at about $467,000. Candriam S.C.A. bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at about $256,000. Finally, XTX Topco Ltd boosted its position in shares of CytomX Therapeutics by 382.6% during the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 48,033 shares during the last quarter. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Trading Down 9.0 %

Shares of NASDAQ CTMX opened at $0.91 on Monday. The stock has a market cap of $71.22 million, a price-to-earnings ratio of 5.35 and a beta of 1.06. CytomX Therapeutics, Inc. has a 1-year low of $0.91 and a 1-year high of $5.85. The stock’s 50-day moving average is $1.12 and its 200 day moving average is $1.45.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. The company had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period last year, the firm posted $0.04 EPS. On average, analysts forecast that CytomX Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research report on Monday, November 11th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, CytomX Therapeutics has an average rating of “Hold” and a consensus price target of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.